NASDAQ:ANIK Anika Therapeutics - ANIK Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $31.21 -0.89 (-2.77%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$31.20▼$32.2050-Day Range$27.89▼$32.1052-Week Range$19.95▼$33.18Volume44,401 shsAverage Volume68,708 shsMarket Capitalization$455.98 millionP/E RatioN/ADividend YieldN/APrice Target$28.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Anika Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside8.7% Downside$28.50 Price TargetShort InterestHealthy3.79% of Float Sold ShortDividend StrengthN/ASustainability-1.77Upright™ Environmental ScoreNews Sentiment0.66Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.45) to ($0.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector773rd out of 1,027 stocksSurgical & Medical Instruments Industry81st out of 105 stocks 1.3 Analyst's Opinion Consensus RatingAnika Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.50, Anika Therapeutics has a forecasted downside of 8.7% from its current price of $31.21.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.79% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Anika Therapeutics has recently decreased by 17.28%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnika Therapeutics has received a 46.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Medical splints", and "Medical screws" products. See details.Environmental SustainabilityThe Environmental Impact score for Anika Therapeutics is -1.77. Previous Next 3.1 News and Social Media Coverage News SentimentAnika Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Anika Therapeutics this week, compared to 2 articles on an average week.Search Interest6 people have searched for ANIK on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Anika Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.03% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions91.57% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Anika Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -28.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -28.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anika Therapeutics (NASDAQ:ANIK) StockAnika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.Read More Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIK Stock News HeadlinesFebruary 5, 2023 | marketwatch.comInjectable Hyaluronic Acid Fillers Market Positioning and Booming Industry Share Worldwide with Massive Growth Opportunities to 2029February 3, 2023 | finance.yahoo.comGlobal OTC Hyaluronic Acid Market 2022 to 2027 - Featuring Anika Therapeutics, Contipro, Galderma and LG Life Sciences Among OthersFebruary 6, 2023 | Investing Trends (Ad)New "Vertical" Technology Solves Solar Power's Major FlawEven conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.February 3, 2023 | americanbankingnews.comHead-To-Head Analysis: RenovaCare (OTCMKTS:RCAR) & Anika Therapeutics (NASDAQ:ANIK)February 2, 2023 | marketwatch.comHow and Where the Topical Hemostatic Agents Market 2023 is Set to Grow in forecast period 2028January 30, 2023 | finance.yahoo.comAnika Therapeutics (ANIK) Dips More Than Broader Markets: What You Should KnowJanuary 30, 2023 | americanbankingnews.comAnika Therapeutics, Inc. (NASDAQ:ANIK) Short Interest UpdateJanuary 24, 2023 | marketwatch.comSoft Tissue Repair Market 2023 to 2029 by Key Players Atrium Medical, Baxter, BioHorizons, Anika TherapeuticsFebruary 6, 2023 | Investing Trends (Ad)New "Vertical" Technology Solves Solar Power's Major FlawEven conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.January 20, 2023 | marketwatch.comCosmetic Procedures Market 2023 is progresses across Industrial Capabilities with Statistical Significance Owing, Investment FeasibilityJanuary 19, 2023 | uk.finance.yahoo.comGlobal Viscosupplementation Market Report 2022: Featuring Anika Therapeutics, Sanofi, Zimmer Biomet, F.Hoffmann-La Roche & MoreJanuary 18, 2023 | nz.finance.yahoo.comGlobal Viscosupplementation Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company AnalysisJanuary 18, 2023 | marketwatch.comProfessional Aesthetic Device Market 2023 : Regional Trade, Company Profile Analysis, Business Strategies and PESTEL Analysis by 2029January 18, 2023 | marketwatch.comSports Medicines Market 2023 Research Strategies and Growth Statistics by Key Vendors as Anika Therapeutics, Arthrex, Breg, BSN MedicalJanuary 17, 2023 | marketwatch.comHyaluronic Acid (HA) Raw Material Market 2023 : Trends, Industry Structure, Development, Demographics, Developing Factors By 2029January 16, 2023 | marketwatch.comAbsorbable Anti-Adhesion Products Market 2023 by Industry Growth, Size, Trends, Share, Opportunities and Forecast To 2029January 16, 2023 | marketwatch.comHyaluronic Acid Solution Market Size 2023 with the increasing need to extend Outlook 2028January 15, 2023 | marketwatch.comHyaluronic Acid (HA) Raw Material Market Size 2023 with Economical benchmarking, Old statistics & forecasts, Company returns sharesJanuary 13, 2023 | marketwatch.comOrthobiologics Market is Taking Hike in Revenue Along With Top Key Players Profile and Forecast 2023 To 2028January 13, 2023 | marketwatch.comExplore Why Hyaluronic Acid Based Dermal Fillers Market With Massive Data and Availability to Hamper the Industry GrowthJanuary 12, 2023 | marketwatch.comAn Overview of Non-Surgical Bio-Implants Market, Major Participants, and Prospects by 2028January 11, 2023 | marketwatch.comDermal Filler Injections Market is booming in near Future 2023-2029January 10, 2023 | marketwatch.comGlobal Emergency Hemostatic Agent Market Size 2023 Research Report by Future Demands, Share, Types, Trends, Sales, Revenue and Forecast 2028January 10, 2023 | marketwatch.comOrthopedic Hyaluronic Acid Market : Projections and Regional Outlook, Set for Rapid Growth and Trend by 2023 To 2028January 10, 2023 | marketwatch.comHyaluronic Acid Viscosupplementation Market Trends, Business Overview, Industry Growth, and Forecast 2023 To 2028January 9, 2023 | marketwatch.comJoint Pain Injections Market : Latest Trends, Size, Key Players, Revenue and Forecast 2028January 9, 2023 | finance.yahoo.comBiogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer'sSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIK Company Calendar Last Earnings11/08/2022Today2/06/2023Next Earnings (Estimated)3/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ANIK CUSIP03525510 CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees297Year Founded1992Price Target and Rating Average Stock Price Forecast$28.50 High Stock Price Forecast$31.00 Low Stock Price Forecast$26.00 Forecasted Upside/Downside-8.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$4.13 million Net Margins-10.33% Pretax Margin-14.12% Return on Equity-2.49% Return on Assets-2.05% Debt Debt-to-Equity RatioN/A Current Ratio6.37 Quick Ratio4.95 Sales & Book Value Annual Sales$147.79 million Price / Sales3.09 Cash Flow$1.37 per share Price / Cash Flow22.70 Book Value$19.89 per share Price / Book1.57Miscellaneous Outstanding Shares14,610,000Free Float14,167,000Market Cap$455.98 million OptionableOptionable Beta0.92 Social Links Key ExecutivesCheryl Renee BlanchardPresident, Chief Executive Officer & DirectorAnne NunesVice President-OperationsMichael L. LevitzChief Financial Officer, Treasurer & EVPMira LeiwantVP-Quality, Regulatory & Clinical AffairsSteven W. EkVice President-Research & DevelopmentKey CompetitorsOraSure TechnologiesNASDAQ:OSURCerusNASDAQ:CERSUtah Medical ProductsNASDAQ:UTMDAtrionNASDAQ:ATRIApollo EndosurgeryNASDAQ:APENView All CompetitorsInsiders & InstitutionsFisher Asset Management LLCBought 13,622 shares on 2/3/2023Ownership: 0.910%Legato Capital Management LLCBought 7,556 shares on 2/1/2023Ownership: 0.052%Comerica BankSold 2,530 shares on 1/26/2023Ownership: 0.060%Ziegler Capital Management LLCSold 5,051 shares on 1/24/2023Ownership: 0.127%Louisiana State Employees Retirement SystemBought 6,900 shares on 1/24/2023Ownership: 0.047%View All Insider TransactionsView All Institutional Transactions ANIK Stock - Frequently Asked Questions Should I buy or sell Anika Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIK shares. View ANIK analyst ratings or view top-rated stocks. What is Anika Therapeutics' stock price forecast for 2023? 2 brokerages have issued twelve-month price objectives for Anika Therapeutics' stock. Their ANIK share price forecasts range from $26.00 to $31.00. On average, they anticipate the company's stock price to reach $28.50 in the next twelve months. This suggests that the stock has a possible downside of 8.7%. View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts. How have ANIK shares performed in 2023? Anika Therapeutics' stock was trading at $29.60 at the start of the year. Since then, ANIK shares have increased by 5.4% and is now trading at $31.21. View the best growth stocks for 2023 here. Are investors shorting Anika Therapeutics? Anika Therapeutics saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 542,800 shares, a decrease of 17.3% from the December 31st total of 656,200 shares. Based on an average daily trading volume, of 101,400 shares, the days-to-cover ratio is presently 5.4 days. Approximately 3.8% of the shares of the stock are short sold. View Anika Therapeutics' Short Interest. When is Anika Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023. View our ANIK earnings forecast. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics, Inc. (NASDAQ:ANIK) announced its quarterly earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.13. The biotechnology company had revenue of $40.26 million for the quarter, compared to analysts' expectations of $36.56 million. Anika Therapeutics had a negative net margin of 10.33% and a negative trailing twelve-month return on equity of 2.49%. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND). What is Anika Therapeutics' stock symbol? Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK." Who are Anika Therapeutics' major shareholders? Anika Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.91%), Allspring Global Investments Holdings LLC (0.33%), Assenagon Asset Management S.A. (0.33%), Ziegler Capital Management LLC (0.13%), Los Angeles Capital Management LLC (0.07%) and Riverwater Partners LLC (0.07%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, James Loerop, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land. View institutional ownership trends. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Anika Therapeutics' stock price today? One share of ANIK stock can currently be purchased for approximately $31.21. How much money does Anika Therapeutics make? Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $455.98 million and generates $147.79 million in revenue each year. The biotechnology company earns $4.13 million in net income (profit) each year or ($1.09) on an earnings per share basis. How many employees does Anika Therapeutics have? The company employs 297 workers across the globe. How can I contact Anika Therapeutics? Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720. This page (NASDAQ:ANIK) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.